Advanced search
Publication Cover
Molecular & Cellular Oncology Volume 5, 2018 - Issue 4
Submit an article Journal homepage
1,078
Views
1
CrossRef citations to date
0
Altmetric
Author's Views

CDC25 as a common therapeutic target for triple-negative breast cancer - the challenges ahead

Eldad ZacksenhausToronto General Research Institute - University Health Network, Toronto, Ontario, Canada;Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, Canada;Department of Medicine, University of Toronto, Toronto, Ontario, CanadaCorrespondence[email protected]
View further author information
,
Jeff C. LiuToronto General Research Institute - University Health Network, Toronto, Ontario, CanadaView further author information
,
Letizia GranieriToronto General Research Institute - University Health Network, Toronto, Ontario, Canada;European Institute of Oncology, Milan, ItalyView further author information
,
Ioulia VorobievaToronto General Research Institute - University Health Network, Toronto, Ontario, Canada;Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, CanadaView further author information
,
Dong-Yu WangToronto General Research Institute - University Health Network, Toronto, Ontario, CanadaView further author information
,
Ronak Ghanbari-AzarnierToronto General Research Institute - University Health Network, Toronto, Ontario, Canada;Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, CanadaView further author information
,
Huiqin LiToronto General Research Institute - University Health Network, Toronto, Ontario, CanadaView further author information
,
Amjad AliToronto General Research Institute - University Health Network, Toronto, Ontario, CanadaView further author information
,
Philip E.D. ChungToronto General Research Institute - University Health Network, Toronto, Ontario, Canada;Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, CanadaView further author information
,
YoungJun JuToronto General Research Institute - University Health Network, Toronto, Ontario, CanadaView further author information
,
Zhe JiangToronto General Research Institute - University Health Network, Toronto, Ontario, CanadaView further author information
&
Mariusz ShresthaToronto General Research Institute - University Health Network, Toronto, Ontario, Canada;Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, CanadaView further author information
 show all
Article: e1481814 | Received 16 May 2018, Accepted 16 May 2018, Published online: 15 Aug 2018

References

  • Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, Wang S, Herschkowitz JI, Egan SE, Perou CM, et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle. 2011;10(10):1563–1570. doi:10.4161/cc.10.10.15703.
  • Zacksenhaus E, Shrestha M, Liu JC, Vorobieva I, Chung PED, Ju Y, Nir U, Jiang Z. Mitochondrial OXPHOS induced by RB1 deficiency in breast cancer: implications for anabolic metabolism, stemness, and metastasis. Trends Cancer. 2017;3(11):768–779. doi:10.1016/j.trecan.2017.09.002.
  • Condorelli R, Spring L, O’Shaughnessy J, Lacroix L, Bailleux C, Scott V, Dubois J, Nagy RJ, Lanman RB, Iafrate AJ, et al. Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. Ann Oncol. 2018; 29(3):640–645. doi:10.1093/annonc/mdx784.
  • Jones RA, Robinson TJ, Liu JC, Shrestha M, Voisin V, Ju Y, Chung PE, Pellecchia G, Fell VL, Bae S, et al. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation. J Clin Invest. 2016; 126(10):3739–3757. doi:10.1172/JCI81568.
  • Kitajima S, Yoshida A, Kohno S, Li F, Suzuki S, Nagatani N, Nishimoto Y, Sasaki N, Muranaka H, Wan Y, et al. The RB-IL-6 axis controls self-renewal and endocrine therapy resistance by fine-tuning mitochondrial activity. Oncogene. 2017; 36(36):5145–5157. doi:10.1038/onc.2017.124.
  • Witkiewicz AK, Chung S, Brough R, Vail P, Franco J, Lord CJ, Knudsen ES. Targeting the vulnerability of RB tumor suppressor loss in triple-negative breast cancer. Cell Rep. 2018;22(5):1185–1199. doi:10.1016/j.celrep.2018.01.022.
  • Liu JC, Granieri L, Shrestha M, Wang DY, Vorobieva I, Rubie EA, Jones R, Ju Y, Pellecchia G, Jiang Z, et al. Identification of CDC25 as a common therapeutic target for triple-negative breast cancer. Cell Rep. 2018; 23(1):112–126. doi:10.1016/j.celrep.2018.03.039.
  • Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer. 2007;7(7):495–507. doi:10.1038/nrc2169.
  • Lavecchia A, Di Giovanni C, Pesapane A, Montuori N, Ragno P, Martucci NM, Masullo M, De Vendittis E, Novellino E. Discovery of new inhibitors of Cdc25B dual specificity phosphatases by structure-based virtual screening. J Med Chem. 2012;55(9):4142–4158. doi:10.1021/jm201624h.
  • Robinson TJ, Pai M, Liu JC, Vizeacoumar F, Sun T, Egan SE, Datti A, Huang J, Zacksenhaus E. High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: interaction with IQ motif-containing factors. Cell Cycle. 2013;12(18):3013–3024. doi:10.4161/cc.26063.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.